According to the pathogenesis of SS, biological agents for the treatment of SS primarily affect the number of B cells, such as rituximab, or inhibit expression of BAFF, which is a target protein for B cell proliferation and/or activation, such as belimumab (19, 73). Here, TNFSF13B is linked to synovial sarcoma.